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Summary
Eosinophils account for 1 - 3% of peripheral blood leukocytes and accumulate at 
local inflammatory sites in allergic conditions such as asthma and allergic rhinitis. 
Eosinophils contain four cationic granule proteins, Eosinophil Peroxidase (EPO), 
Eosinophil Derived Neurotoxin (EDN), Eosinophil Cationic Protein (ECP) and 
Major Basic Protein (MBP) and all are highly toxic at high concentration.
However, these eosinophil granule proteins exhibit positive effects at a lower, 
more physiological concentration, such as cell and tissue remodelling and growth 
factor receptor expression. Eosinophils localise to epithelial cells in vivo and this 
study looks at the effect of eosinophil granule proteins on human bronchial 
epithelial cells.
In this study, we present evidence that EPO forms a complex with and activates 
the HER2 receptor, with consequent upregulation of HER2 receptor expression. 
This EPO-HER2 interaction is dependent on N-linked glycosylation. We also 
provide evidence that, subsequent to HER2 activation, EPO induces activation of 
pi integrin, activation of FAK and activation of ERK. The activation of FAK and 
p1 integrin is dependent on the initial activation of the HER2 receptor. The 
activation of FAK is independent of pi-integrin activation and the activation of 
ERK is delayed in the absence of pi integrin activation. We also found an EPO- 
induced, HER2-dependent upregulation of MUC4 at a transcriptional level.
These results suggest that eosinophil localisation to epithelial cells, as seen in 
asthma and rhinitis, induces growth factor receptor expression and activation of 
subsequent downstream pathways associated with cell proliferation, all of which 
are necessary for the airway to repair and remodel after an inflammatory 
episode. EPO-induced upregulation of MUC4 gene expression indicates that 
eosinophils may also contribute to increased mucociliary clearance during an 
inflammatory attack.
I l l
1. Introduction
The normal epithelium comprises a monolayer of cells, of which there are many 
types, each with their own function. The overall function of the airway epithelial 
layer is to allow gaseous exchange within the body and to protect the host from 
invasion by pathogens.
In healthy airway epithelium, one of the first lines of defence is the mucus that 
sits on top of the cilia and lines the trachea and bronchi. It acts as a physical 
barrier to foreign particles and traps pathogens before they can enter the lung.
An important function of the cilia within the nasal passage is to again trap any 
pathogens before they can enter the lung and also to facilitate mucociliary 
clearance. When these methods fail and the airways become exposed to 
pathogens/allergens (Diagram 1), the pulmonary epithelial cells have the ability 
to recruit cells of the innate and adaptive immune systems.
Asthma is an airway disease in which there is a disrupted epithelium, a 
breakdown in tight junctions between cells and an increase in epithelial 
permeability. These features are due to chronic inflammation. The chronic 
inflammation seen in asthma is due to the development of an adaptive immunity 
to an allergen and augmented by viral infection. Repeated exposure to the 
allergen results in an increased inflammatory reaction and continuous damage to 
the airways [1]. A T helper type 2 (TH2) type inflammatory response is seen in 
asthma [2], alongside an excess of eosinophils, mast cells and activated T helper 
lymphocytes, which leads to bronchoconstriction, mucus secretion and 
remodelling, mediated by factors including chemokines, cytokines and growth 
factor receptors [1].
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Diagram 1. Normal versus Asthmatic Airway Epithelium
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1.1 Eosinophils
Eosinophils account for 1 - 3% of peripheral blood leukocytes. They are best 
known for their role in defence against parasites and are found to be 
accumulated at sites of inflammation in allergic disorders such as asthma and 
allergic rhinitis [3-5], Eosinophils have also been implicated in other disease 
states such as inflammatory bowel disease [6], parasitic helminth infection [7] 
and cancer [8]. Eosinophils also play a role in normal mammary gland 
development [9] and in pregnancy [10]. Hence, there is a wide variety of 
circumstances in which eosinophils play a role. The shared characteristic of 
many of these physiological and pathological conditions is that there is excessive 
cell turnover.
E o s in o p h i l
asthma
irritable
bowel
disease
parasitic
helminth
infection
pregnancy
allergic
rhinitis
Cancer
normal
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gland
development
Diagram 2. Eosinophils are implicated in many physiological and pathological
conditions, all of which are associated with increased cell turnover.
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1.1.1 Eosinophil Structure and Function
Eosinophils have a bi-lobed nucleus and contain secondary/specific granules. 
Within these granules there are a number of cationic granule proteins, which 
when released can be highly toxic to cells such as epithelial cells. These granule 
proteins include, Major Basic Protein (MBP), Eosinophil Peroxidase (EPO), 
Eosinophil Derived Neurotoxin (EDN) and Eosinophil Cationic Protein (ECP) [3], 
Eosinophils also produce and release inflammatory mediators such as 
interleukin-5 (IL-5) and eotaxin. These mediators intensify the inflammatory 
response by recruiting and activating further eosinophils. Recent discoveries 
suggest that eosinophils undergo piecemeal degranulation (PMD) where 
eosinophil granules undergo selective release of their protein contents, 
determined by the activation stimulus [11].
Eosinophil
ll__5 eotaxin
ECP EPO
Diagram 3. Eosinophils release four cationic granule proteins and inflammatory 
mediators such as IL-5 and eotaxin
The proliferation and differentiation of eosinophils in the bone marrow occurs at a 
constant level. Stimulation of TH2 causes an increase in the proliferation and 
differentiation of eosinophils. TH2 lymphocytes are activated to produce cytokines 
(e.g. IL-5) and this increases the production of eosinophils in the bone marrow 
and promotes their release into the circulation [12]. The migration of eosinophils 
from blood circulation to various tissues is dependent on chemoattractants such 
as eotaxin (an eosinophil-specific chemokine) [13]. The granule proteins are 
released when the eosinophils become exposed to soluble mediators (e.g. 
immunocomplexes or solid particles) [14-15]. Blood eosinophils are known to be 
an indirect marker of airway inflammation in asthma and there is a correlation 
between the number of blood eosinophils and the severity of asthma [3].
1.1.2 Eosinophil Peroxidase (EPO)
EPO is a 77,000 Da protein with two sub-units. It is a member of the animal 
peroxidase superfamily and its gene is located on chromosome 17 [16-17]. The 
neutrophil myeloperoxidase shares -70% amino acid homology with EPO [18]. 
Approximately 25% of the total protein mass of specific eosinophil granules is 
comprised of EPO, and EPO forms highly reactive oxygen species by catalyzing 
the oxidation of pseudohalides, halides, nitric oxide and reactive nitrogen 
metabolites [19]. EPO is present in the matrix of the eosinophil granules and 
when released, EPO along with the other granule proteins, function in modulating 
various immune responses and in contributing to the initiation of inflammatory 
responses [19].
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1.1.3 The Eosinophil Controversy
The increased presence of eosinophils correlates with an increase in the 
destruction of the epithelium. Specific remodelling effects thought to be at least 
partly eosinophil-mediated include, thickening of the basement membrane- 
associated structures and smooth muscle hypertrophy. These features of 
remodelling in the lungs of asthmatics are reversed by inhibition of eosinophil 
recruitment to the lung [20].
Until recently, research into eosinophils and their role in the human body focused 
mainly on their destructive properties, due to their significantly increased 
presence at sites of inflammation and in the various diseases as mentioned 
earlier, their cytotoxic peroxidase activity, and their toxic cationic character [20- 
21].
The accumulation of eosinophils in allergic asthma is no longer seen as a 
causative factor of inflammation, solely associated with tissue and airway 
destruction, but their recruitment is now linked with immunoregulation (as 
described earlier, Section 1.1.1), thus giving eosinophils an effector function 
which could possibly be the primary purpose of their recruitment [21]. Hence, 
eosinophils are now linked to more subtle effects on airway re-modelling, 
epithelial repair and mucin production from epithelial cells in airway diseases 
such as asthma.
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Diagram 4. The Eosinophil Controversy.
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1.2 Mucins
Mucins are the major macromolecular constituents of epithelial mucus. Mucins 
may be either membrane associated or secretory. MUC4 is a membrane tethered 
mucin and is also a tethered ligand for the HER2 member of the epidermal 
growth factor receptor (EGFR) family [23-24]. Mucins are implicated in health and 
disease, specifically in chronic airway diseases where mucin overproduction is 
apparent. Mucin glycoproteins function in mucociliary clearance and they also 
contribute to innate immunity in the pulmonary epithelium [22]. Thirteen human 
membrane associated mucin and mucin-like genes exist. MUC1, MUC4 and 
MUC16 are expressed in the lungs [25]. Both MUC1 and MUC4 dimerise with 
and regulate HER family epidermal growth factor receptors [26].
CHRONIC
Mucin overproduction 
Goblet Cell hyperplasia 
Glandular hyperplasia
Environmental Toxins/Pathogens ♦
Inflammatory/Immune Response/Mediators
Submucosal Gland
Mucus obstruction in the airways: 
Asthma, CF, Bronchitis
ACUTE
Mucin Hypersecretion 
Mucin overproduction
tMUC gene expression
Submucosal Gland
Diagram 5. Picture from; Rose, M.C. and J.A. Voynow, Respiratory tract mucin genes 
and mucin glycoproteins in health and disease. Physiol Rev, 2006. 86(1): p. 245-78
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1.3 Epidermal Growth Factor Receptor (HER) Family
1.3.1 Structure and Function
HER family receptors are single-chain modular glycoproteins that exist on the 
surface of cells. They contain an extracellular ligand binding domain (-620 
residues), a transmembrane domain (-23 residues) and an intracellular tyrosine 
kinase domain (-260 residues). Each domain is responsible for a different aspect 
of HER signalling pathways [27]. The extracellular region is heavily glycosylated 
by glycans (the carbohydrate portion of a proteoglycan) and 9 of the 11 potential 
glycosylation sites are utilised. Twenty percent of the molecular mass of EGFRs 
is carbohydrate [28]. There are four structurally related family members which 
interact with each other, i.e. HER1 (EGFR/ErbB1), HER2 (ErbB2/neu), HER3 
(ErbB3) and HER4. There is no known soluble ligand for HER2, which acts as a 
co-receptor, forming hetero-dimers with other EGFR family members [29], 
whereas HER1, HER3 and HER4 are associated with one or more specific 
ligands [27] (Diagram 5).
Ligand binding leads to a conformational change in the HER family receptor, 
allowing the receptor to associate with another HER family receptor. This is 
known as dimerization [30]. The intracellular tyrosine kinase domains of the 
dimerized receptors then become activated through transphosphorylation. Many 
carcinomas are promoted by EGFR activation and HER family receptors may be 
inappropriately activated in cancer. Tumours that express HER family receptors 
and their ligands can initiate stimulation of their own growth [31]
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Diagram 6 . The HER family of receptors and their associated
ligands. Image from www.cancerqrace.org as adapted from Rokoski, Biochem
Biophys Res Commun. 2004; 319:1 and Rowinsky. Annu Rev Med. 2001;
55:433.
There exists 6 known ligands for HER1; Epidermal Growth Factor (EGF), 
Transforming Growth Factor-alpha (TGF-a), Amphiregulin, Betacellullin, Heparin- 
Binding Epidermal Growth Factor (HB-EGF) and Epiregulin. There are no known 
soluble ligands for HER2. Heregulins act as ligands for both HER3 and HER4 
and HER4 acts as a receptor for Neuregulin 2 (NRG2), Neuregulin 3 (NRG3) and 
Betacellulin. The epidermal growth factor receptor family members HER1, HER2, 
HER3 and HER4 are also known as erb-b1, erb-b, erb-b3 and erb-b4, 
respectively. HER1 and HER2 are also known as EGFR and neu, respectively.
All four receptors exert tyrosine kinase activity apart from HER3, as indicated by 
the yellow cross on its intracellular domain.
10
1.3.2 HER2
HER2 is the preferred partner of the other three HER family receptors, but other 
dimer pairs do exist. HER2 is able to decrease the rate of ligand dissociation 
from its dimerized partner [32]. EGFR (HER1) is a ligand-dependent tyrosine 
kinase [33], and HER3 is the receptor to multiple ligands but has no tyrosine 
kinase activity. No known soluble ligand for HER2 exists, yet it still retains 
tyrosine kinase activity [34]. It exists in a pre-activated state, allowing the binding 
of a dimer partner without activation by a ligand [27]. MUC4 functions as a 
tethered, endogenous HER2 ligand and influences HER2 activation [35-37]. 
HER2 over-expression is notably associated with several human cancers, 
particularly breast and ovarian [38-40].
1.3.3 Downstream signalling
HER2, when dimerized with HER3, activates both the PI3K and the ERK 
signalling pathway [41-42]. HER2/HER1 dimers are of importance, particularly in 
ovarian cancers. Activation of the HER2/HER1 dimer leads to initiation of the 
mitogen activated protein kinase (MAPK) pathway, which leads to cell 
proliferation [43].
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1.3.3.1 Mitogen Activated Protein Kinase (MAPK) pathway
The MAP kinase pathway, through action of a phosphorylation cascade, allows 
the amplification of certain signals from the extracellular regions to the nucleus, 
which ultimately affects cellular processes such as proliferation, differentiation 
and development [44], The MAPK cascade can be initiated by growth factors, but 
also by ligands for some transmembrane receptors [44]. Mitogen-activated, ERK 
activating kinase (MEK) and ERK are the principle isoforms in growth factor 
signalling [44]. Growth factors initiate the ‘classical’ MAP kinase pathway 
(Diagram 7), whereby activated receptors recruit Ras guanine nucleotide 
exchange factors such as son of sevenless (SOS) through the adapter protein 
GRB2 (growth factor receptor-bound protein2), which activates or recruits Ras, a 
small GTPase that binds to and recruits Raf kinases to the cell membrane for 
subsequent activation. Raf phosphorylates and activates MEK, MEK 
phosphorylates and activates ERK/MAPK. THE MAPK signalling cascade, 
however, is not a simple linear pathway; different isoforms of the various 
components exist, all with different functions, leading to a branched pathway 
system. The combinations of pathway routes are reviewed in [45].
/
Diagram 7. A basic overview of the MAP Kinase Pathway
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1.4 Integrins
Integrins are one o f the  m a jo r fam ilies  o f cell adhesion  receptors. T h e  com p le te  
m am m alian se t o f in tegrins com prises 8 a  and 18p subun its , g iv ing 24  d is tin c t a /p  
hete rod im eric  in tegrins, each w ith  d iffe ren t ligand sp e c ific ity  [46].
1.4.1 Integrin Function
Integrins, as th e ir fam ily  nam e suggests, fun c tio n  in fac ilita ting  cell adhesion  to  
the extrace llu la r m a trix  (EC M ). A dh e ren t cells, w h ich  inc lude  ep ithe lia l cells, m ust 
be attached to th e ir ECM in o rde r to surv ive  [47].
Integrins act as a link betw een ex trace llu la r and in tra ce llu la r s ignals  and as a 
resu lt a ffec t num erous cell characte ris tics, inc lud ing  pro life ra tion , 
su rv iva l/apop tosis, shape, polarity, m otility, gene  express ion  and d iffe ren tia tion  
[46], In tegrins a lso regu la te  sod ium -pro ton  anti-porte rs , w h ich  contro l changes in 
in trace llu la r pH [48]. A ctiva tion  o f th is sod ium -pro ton  an ti-po rte r is enhanced  by 
the s im ultaneous e ng age m en t o f both  in teg rins  and g row th  fa c to r recepto rs  [48- 
49]. There  are fo u r d iffe ren t va rian ts  o f the p1 in tegrin  su bun it (P1A, p iB ,  p iC  
and p i  D). The  cy top lasm ic  tail o f the  in tegrin  p subun its  are  respons ib le  fo r 
associating  w ith  a dap te r p ro te ins tha t conne ct the  in tegrin  to the  cytoske le ton  as 
w ell as to  transm em brane  g row th  fa c to r recep to rs  [47].
1.4.2 Integrin Activation
The contro l o f in tegrin  activation  is im portan t th rou g ho u t d eve lo pm ent and in 
adu lt life [50], as its uncontro lled  activa tion  can have m any im plica tions in health 
and d isease. A s  review ed in M iranti and B rugge  2002, p1 conta in ing  in tegrins (as 
w ell as m ost leukocyte  and p la te le t in tegrins) e x is t in a resting state  until 
activated by stim uli and m u ltip le  agon is ts  can regula te  ind iv idual in tegrins [49], 
u ltim ate ly leading  to  in tegrin -m edia ted  ce ll-s igna lling.
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1.4.3 Integrin Signalling
In tegrins span the cell m em brane, and can thu s signal b id lrec tio na lly  be tw een 
the in tegrin  cy top lasm ic  tail and th e  e x trace llu la r ligand-b ind ing  dom ain  [49]. The  
cytop lasm ic dom ain  is m uch la rge r (a pprox im ate ly  50 am ino  ac ids) than  the 
extrace llu la r dom ain. It is the  cy top lasm ic  dom ain  tha t fac ilita te s  in teraction  w ith  
the cytoske le ta l and s ignalling  partners o f in tegrins, th rough  in teraction  and 
linkage [46]. In te ractions o f activating  p ro te ins w ith  the p i  in tegrin  tail leads to 
conform ationa l changes across the  m em brane  to  the  e x trace llu la r dom ains w h ich  
increases the  in teg rins ’ a ffin ity  fo r  ligands [51] (D iagram  8). T h e  m echan ism  by 
w hich in tegrins, upon activation , tra nsm it s ignals across the  m em brane, begins 
w ith  a change  in the packing o f the  a  and p tra nsm em brane  dom ains. The  
dom ains e ithe r separa te, ro tate  o r ch ange  in the ir re la tive  position  in the 
m em brane. T h is  is fo llow ed by a lte ra tion  o f the  ligand b ind ing  site  in the  in tegrin  
ectodom ain  [52], Zhu  et al. found th a t the  separa tion  o f a  and p subun it 
transm em brane  helices w as required fo r  in tegrin  ou ts ide-in  s ignalling  [53].
cell
membrane
-phospholipid
bilayer
alteration of 
ligand binding 
site in the integrin 
ectodomain
after interaction with 
activating protein 
a conformational 
change occurs in 
integrin tail
Diagram 8. Integrins spanning the cell membrane.
1. in tegrins in resting state. 2. in tegrins a fte r in trace llu la r activation
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1.4.4 Integrin Signalling Molecules
In tegrins act as s ignalling  recep to rs  as w e ll as m ed ia to rs o f cell adhesion  [46,
49], In tegrins d irectly  activa te  m any pro te in  tyros ine  k inases such as foca l 
adhesion  k inase (FAK), S rc-fam ily  k inases (S FK s) and in tegrin  linked k inase 
(ILK) w hich is a serine -th reon ine  kinase [47], N um erous o th e r s igna lling  pro te ins 
are activated dow nstream  o f in tegrin  activa tion , includ ing  the  M AP kinase 
pathw ay, Ras, Raf, M EK and ER K [49].
FAK is a prote in  tyros ine  k inase  w h ich  is activated  by in tegrins. It has a 
re la tive  m o lecu la r w e igh t o f 120,000 Da. FAK w as o rig in a lly  identified  as a v -S rc  
substra te  [54], and w as found to  loca lise  to foca l adhesions [49, 55], due  to its C- 
te rm ina l foca l-adhes ion -ta rge ting  (FA T) dom ain  tha t in te racts  w ith  ta lin  and 
paxillin  [49]. FAK is activated  by g row th  fac to rs  and o the r agon is ts  in add ition  to  
in tegrins [56]. Th is  m eans th a t FAK  in tegra tes s igna ls  fo r  g row th  by acting as a 
link betw een in tegrins and g row th  fa c to r receptors. H ence, FA K  is o f in te rest to 
us in re lation to possib le  e ffects  o f eosinophil pro te in  on the  cell.
1.4.5 Integrin de-activation/dis-engagement
Integrin  d iseng age m en t occurs  w hen the  cell no longer requ ires the  in tegrin  to be 
in its active  state  (e.g. w hen  cell is m igrating), and th is  invo lves  d issoc ia tion  o f 
the various p ro te in -in tegrin  in te rac tions  in a contro lled  m an ner [57]. M any 
m echan ism s and op tions  ex is t fo r  inh ib iting  in tegrin  activa tion  due to  the  vast 
num ber o f p ro te ins tha t in te ract w ith  them . In trace llu la r in tegrin -s igna lling  
pro te ins can com pete  fo r b inding to  the  p-tail (e.g. ta lin ) [57], the re fo re  a ltering 
the s tructure  o f the in tegrin  adh esom e and the confo rm ation  o f the in tegrin  
helices, resulting in an a ltered  ligand b inding dom ain  s tructure . In te resting ly  fo r 
th is project, inh ib ition o f FAK  (a key co m pone n t in the active  in tegrin  pro te in  
c luster) leads to  the  d isassem bly  o f foca l contacts  [58]. T h is  again show s the 
im portance  o f investiga ting  the  in teraction  betw een FAK and in tegrins in hum an 
bronch ia l epithe lia l cells.
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1.4.6 Integrins and Growth Factor Receptors
Integrins m ake m any im portan t d irect o r ind irect in te rac tions  w ith  transm em brane  
signalling  prote ins, includ ing  those  from  the g row th  fa c to r re cep to r fam ilies.
Som e so luble  g row th  facto rs , inc lud ing  EG F are  d ep end en t on in teg rin -m edia ted  
ce ll-substra te  a dherence  in o rd e r to  exert th e ir ce llu la r responses. P athw ays 
stim ulated by in tegrins  are s im ila r to and c lo se ly  coup led  w ith  g row th  fac to r 
recepto r-stim ula ted  pathw ays [46, 59].
Both in tegrins  and g row th  fa c to r recep to rs  s tim u la te  various co m p one n ts  
o f the m itogen-activa ted  pro te in  k inase (M A P K ) pathw ay [59-60 ] (D iag ram  9). 
Integrins can fac ilita te  g row th  fac to r-m ed ia ted  activa tion  o f ER K  [47], and FAK 
(w hose pathw ay is activated  by in tegrins and g row th  fa c to r recep to rs) is linked to 
signalling  pathw ays tha t m od ify  the  cytoske le ton  and activa te  m itogen-activa ted  
prote in  k inase (M A P K ) cascades. Integrin  c lustering  and associa tion  w ith  the 
cytoske le ton  appears  to g ive rise to  in teg rin -g row th  fa c to r recep to r com p lexes 
[47, 61]. The  in teractions and in te rdependence  o f g row th  fa c to r recepto rs  such 
as the H ER fa m ily  and in tegrins is underscored  by obse rva tio ns  such tha t p i  
integrin can fac ilita te  bypassing  o f the anti-p ro life ra tive  e ffec ts  o f the  H ER2 
neutra lis ing a n tibo dy tras tuzum ab  in b reast ca nce r ce lls  [62],
Diagram 9. In teraction  o f in tegrins and ep iderm al grow th fa c to r recep to rs  leads 
to activation o f the  m itogen-activa ted  prote in  kinase (M A P K ) pathw ay
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1.5 N-linked Glycosylation
G lycosyla tion  re fers to the enzym atic  p rocess tha t a ttaches g lycans to  pro te ins, 
lip ids or o the r o rgan ic  m o lecu les. It is a fo rm  o f co -trans la tiona l and post- 
transla tiona l m odifica tion . The  m a jo rity  o f p ro te ins syn thesised  in the  rough 
endop lasm ic re ticu lum  undergo g lyco sy la tion  and the  H ER2 m e m b e r o f the 
Epiderm al G row th  F actor R ecepto r (E G F R ) fa m ily  is heavily  g lycosy la ted . 
G lycosyla tion can be O -linked o r N -linked [63], In O -linked pro te in  g lycosy la tion , 
m ost O -linked ca rbohydra te  cova len t a ttachm ents  to  pro te ins invo lve  a linkage  
betw een the  m onosaccharide  N -A ce ty lga lac tosam ine  and the  am ino  ac ids  serine  
o r threon ine. In N -linked g lycosy la tion , all N -linked ca rbohydra tes  a re  linked 
through N -A ce ty lg lucosam ine  and the  am ino  acid a sparag ine  [66]. N -linked 
g lycosyla tion  w as found  to  p lay a key ro le in the  express ion  leve ls and a c tiv ity  o f 
the EG FR fa m ily  m em ber, H ER2. H ence the  im portance  o f investiga ting  
specifica lly  the ro le  o f N -linked g lycosy la tion  in o u r study [64]. A n  in itia l a im  o f 
th is s tudy w as to  exam ine  the n a tu re  o f the  in teraction  betw een E PO  and H ER2 
and due to  the  ca tion ic  nature  o f EPO, the re  m ay be a charge-based  in teraction  
betw een EPO  and H ER2 via N -linked g lycosy la tion .
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1.6 Preliminary data
The E osinophil P eroxidase  used in our la bora to ry  has been purified  from  
hypereosinoph ilic  patients in a Sod ium  C h lo ride  buffer, pH 4.25. W e  received th is  
EPO  as a kind g ift from  Dr. G erald  G leich, U n ive rs ity  o f U tah. An ELIS A  using 
TM B as a substra te  w as carried  o u t and the  blue co lou r w e  obse rve d  ind ica tes 
the perox idase  activ ity  o f o u r EPO.
Recent p re lim inary  data  fro m  th is  labora to ry  leading up to  th is  p ro ject included 
w ork on IM R 32 nerve cells. A  p ro teom ic screen w as carried o u t on E PO -trea ted  
IM R32 ce lls. P ro te ins tha t exh ib ited  the  m ost s ign ifican t chan ges in response  to 
EPO w ere  fu rth e r stud ied. The  phosphory la tion  o f H ER 2 a t the  a u to ­
phosphory la tion  site  Y 1248  and FAK at the  auto -pho sp ho ry la tion  s ite  Y 397 w as 
found to be increased  2 .61 - and 2.7-fo ld , respective ly, in response  to EPO 
treatm ent. The phosphory la tion  o f H ER2 w as confirm ed by W este rn  b lo tting and 
a H E R 2-dependent, E PO -induced  activa tion  o f ERK w as a lso  fou nd . IM R32 ce lls  
underw ent loss o f the cyc lin -dependen t k inase  inh ib ito r p27kip from  the nucleus in 
response to EPO , and th is again w as depe nde n t on the activa tion  o f HER2. An 
upregu la tion  o f the  p ro life ra tion  m arke r K i67 in response  to E PO  w a s  found, and 
again th is  w as d ependent on H ER 2 activa tion . S om e o f th is  w o rk  w a s  confirm ed 
in HBE (hum an bronch ia l ep ithe lia l) cells, and it w as found th a t EPO , but not 
M BP upregu la tes the transcrip tiona l express ion  o f HER2 and M U C 4.
1 8
1.7 Aims of project
The in itia l a im  o f th is pro ject w as to confirm  previous IM R 32 nerve  cell line 
find ings  in the  norm al hum an bronch ia l ep ithe lia l cell line (16H B E 14o). W e  aim ed 
to dete rm ine  the  m echan ism  and co nseq uen ces o f E PO  e n ga gem en t o f HER2 
and to focu s  on signalling  via the  H E R 2 receptor, gene  and p ro te in  express ion  in 
response to  EPO, and also in tegrin  engagem ent.
S pecific  a im s o f th is  p ro ject were;
1. To  confirm  th a t EPO engages the  H ER 2 recep to r in hum an  bronch ia l 
ep ithe lia l ce lls
2. To investiga te  the  spec ific ity  o f the EPO  and H ER 2 in teraction  in hum an 
bronch ia l epithelia l cells
3. To investiga te  the co nseq uen ces  o f the  E P O -H E R 2 in teraction
4. To investiga te  if p i in tegrin  s ignalling  occurs  in response  to  EPO  
tre a tm en t
5. To  investiga te  if the m echan ism  o f in te raction  betw een EPO  and H ER2 is 
m edia ted  via N -linked g lycosy la tion
6. To  investiga te  if the  in teraction  o f EPO  and H E R 2 resu lted  in any 
dow nstream  consequences a ffecting  cell charac te ris tics  e.g. g row th  and 
surviva l
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2. Materials and Methods
2.1 Cell Culture
16HBE14o cell line: C ells  w ere  cu ltured  in flb ro ne c tin -co a te d  (Tab le  3 .1 .1 ) T75  
tissue  cu lture  flasks, in g row th  m edium  (T ab le  3 .1 .2 ) until app rox im ate ly  80%  
confluent. C ells in the  flask  w ere  then  tryps in ised  by rinsing w ith  w arm  D PBS and 
incubating  at 37°C in 5 ml 1x T ryps in  (1X  5%  T ryps in -E D T A , G ibco) fo r 5 m in. 
G row th m edium  (5 m l) w as then added to  the  flask  to  neu tra lise  the tryps in  and 
the ce lls  w ere  transfe rred  to a 15 ml tube  and centrifuged  a t 1100xg fo r 5 m in at 
room  tem pera ture. The  superna tan t w as d isca rd ed  and the  pe lle t w as 
resuspended in g row th  m edium . F lasks w e re  sp lit 1 in 5 to  fresh  fib ronectin - 
coated flasks fo r continued  culture.
Experiments: Pelle ts w ere  in itia lly  resuspended  in 1 ml g row th  m edium  and 10 pi 
o f ce lls w ere  added to 80 pi m edium  and 10 pi trypan  b lue  fo r counting  and 
assessm ent o f cell v ia b ility  to g ive  a ccura te  cell num bers fo r setting up 
experim ents. D eta ils  o f cell num bers used fo r d iffe ren t types o f experim ents  are 
in separa te  m ethods sections.
Freezing cells: F lasks w e re  sp lit 1 in 2 w hen  fre ez ing  cells. A fte r the norm al 
centrifugation  step, the  pe lle t w as resuspended in 2 ml cryo freez ing  m edium  
(Tab le  3 .1 .4) and 1 m l w a s added to  each o f tw o cryovia ls. T he  v ia ls  w ere  p laced 
at -80°C  fo r 24 h insu la ted  in po lystyrene  before  being m oved to  liquid n itrogen.
Reviving Cells: V ia ls  w ere  taken from  liquid n itrogen  and 500 pi o f w arm  grow th  
m edium  w as added to  the via l and p ipetted  to  de frost the top  layer o f cells, th is 
w as transferred  to a pre -coated  T75  conta in ing  10 ml p re -w arm ed grow th  
m edium . This w as repeated until all the  m ed ia /ce lls  in the  cryovia l had been 
transferred  to one T75  flask.
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2.2 Preparation of whole cell lysates in ‘Relax’ Intracellular Buffer
C ells (2 x1 05/w ell fo r  12-well and 5 x 105/w ell fo r  6 -w e ll) w e re  p la ted on  to 6- o r 
12-well cu lture  d ishes and a llow ed to  g row  fo r  24  h in g row th  m ed ium  (Tab le
3.1.2) before being transfe rred  in to se rum -free  m ed ium  (T ab le  3 .1 .3 ) fo r  p re ­
trea tm ent (or not) w ith  inh ib itors (Tab le  3 .2 .1), w ash ing  w ith  w arm  1X PBS and 
then trea tm ent w ith  EPO  fo r tim es from  0 to 48 h in se ru m -free  m ed ium  (tim es fo r 
d ifferen t experim ents  are  ind ica ted  w ith in  the R esu lts  section). W hen harvested, 
ce lls w ere at a pp rox im a te ly  70%  - 80%  confluency. C e lls  w e re  w ashed  w ith  
w arm  DPBS and p laced a t 4°C  fo r 5 m in. C e lls  w ere  w ashed  tw ice  fo r 10 min 
w ith ice-cold DPBS and p laced at 4 DC during  incubations. Fresh ‘R e lax ’ lysis 
bu ffe r (Tab le  3 .2 .2 ) w as added to the  w e lls  and the ce lls  from  ind iv idual w e lls  
w ere  scraped and co llected  in m icrocen trifuge  tubes on ice. T he  ce lls  w ere  
hom ogenised by puls ing 20 tim es w ith  a m otorised pe lle t pestle  (S igm a) and 
nuclei w ere  rem oved by low  speed ce n trifuga tion  (1500xg /5  m in/4°C ). 
S upernatants w ere  transfe rred  to new  labelled tubes and stored a t -80°C  until 
use. Prote in concen tra tion  w as de te rm ined  using the  B radfo rd  assay [65]. (P la te  
reader: O rig inal M ultiskan EX, LabS ystem s).
21
2.3 Western Blotting
Gel preparation: P ro te ins w ere  subjected to S D S -P A G E  e lec trophores is  using 
the B iorad gel system . S epara ting  and s tacking  gel com position  are  show n in 
Tab le  3.3.1.
A fte r pouring, separa ting  gels w ere  layered w ith  100%  e thano l until set. The 
e thanol w as rem oved and the  4%  stacking  gel w as then  poured on top and 
com bs w ere  inserted. Equal am ounts o f pro te in  per sam p le  (e xact pro te in  
concentra tions per expe rim en t are deta iled  in the R esu lts  section) w e re  d ilu ted  
w ith  nuc lease-free  S D W  (Q iagen) to g ive  equal vo lum es p e r sam ple  and m ixed 
w ith  an equal vo lum e o f SD S sam ple  trea tm e n t b u ffe r (T ab le  3 .3 .2 ) (fo r probing 
w ith  an tibod ies pH ER 2, HER2, ERK2, pER K, pFA K ) o r w ith  p -m ercap toe thano l- 
free  SD S sam ple  tre a tm e n t bu ffe r (active  p i  in tegrin  an tib ody) (Tab le  3 .3.2). 
S am ples w ere  then dena tu red  at 95°C  fo r 5 m in and centrifuged  at 1000xg fo r  10 
sec before  loading in to gels, excep t fo r  p ro te ins to be probed fo r active  p i -  
in tegrin  w h ich  w ere  not hea t-denatured . G els w e re  run a t 250 V, 30 m A per gel 
and 30 W  in 1X running bu ffe r (Tab le  3.3.3). A  pre -sta ined  pro te in  s ize  m arke r 
(B road R ange 7-175kD a, N ew  England B ioLabs Inc.) w as run on each gel.
Gel transfer: G els w e re  rem oved from  the  p lates, cu t to s ize  and p laced in a w et 
blot appara tus (S igm a) fo r tra ns fe r to n itroce llu lose  m em brane  (0 .45 pm pore 
size) in transfe r b u ffe r (T ab le  3.3.4). The  n itroce llu lose  m em brane  and 
surround ing  W hatm an  pape r layers w ere  p re -soaked  in tra ns fe r buffer. The 
system  w as se t up to a llow  prote in  tra ns fe r in the  d irection  from  ca thode  to anode  
overn igh t at 250V, 80m A  and 30W .
Blocking: M em branes w e re  rem oved from  the tra n s fe r appara tus and sta ined 
w ith  Ponceau S to  check  tra n s fe r o f prote in  and ve rify  equa l gel loading.
Ponceau S w as w ashed  o ff w ith  T B S -T  (Tab le  3 .3.6). B lo ts  w ere  b locked fo r  1 h 
at room  tem pera ture  in b locking bu ffe r (5%  M arve l in T B S -T  o r 5% B S A  in 
TBS-T).
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Antibody binding: M em branes w ere incubated  in ind iv idual p rim ary an tibod ies  
d ilu ted in the appropria te  b locking buffer, as show n in T ab le  3.3.7, o ve rn igh t a t 
4°C  w ith  gentle  agita tion . M em branes w ere  then  w ashed  six tim es fo r 5 m in each 
at room  tem pera tu re  in TB S -T , then p laced in the  a pp rop ria te  H R P -con juga ted  
secondary  an tibody d ilu ted  1 in 2000  in b locking  bu ffe r (5%  M arve l) fo r 1 h at 
room  tem p. M em branes w ere  then w ashed  six tim es fo r 5 m in each at room  
tem pera ture  in T B S -T  and once  fo r 2 m in in 1X TBS.
Chemiluminescent detection: M em branes w e re  incubated  in W este rn  B lo tting 
Lum inol R eagent (S anta  C ruz) fo r 1 m in a t room  tem pera tu re . E xcess reagent 
w as b lotted o ff and the b lo ts  w ere  then  p laced in to an x -ray  film  cassette  
betw een sheets  o f c lear p lastic  and exposed to  X -ray  film  (Kodak, X -O m a t LS 
film , S igm a) in the dark room  fo r appropria te  tim es, depend ing  on the  antibody. 
D eve loper and fixe r so lu tions (K odak p rocess ing  chem ica ls  fo r au to rad iog ra phy 
film s, GBX deve lop er/rep len ish er and G B X  fixe r/rep len ishe r, S igm a) w e re  d ilu ted 
in w ater as per the  m anufactu re r’s ins truc tions  in separa te  trays in the  d a rk  room . 
The  film  w as then rem oved, and p laced in d e ve lo p e r until the  s ignal w a s  vis ib le. 
The  film  w as then  rinsed in w a te r and p laced in the  fixer. The  film  w as rinsed 
once m ore w ith  w ater, left to dry and m arked a pp rop ria te ly  w ith  sam ple  o rd e r and 
m arke r size.
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2.4 Immunoprecipitation
16H BE 14o ce lls (5 x 105/w e ll) w e re  grow n and treated  In 6 -w e ll cu ltu re  plates, as 
in section 2.2. Sam ples w ere  se t up in trip lica te  to  ensure  th a t there  w as enough 
prote in . A fte r trea tm ents  (outlined in R esults), the  ce lls  w ere  rinsed tw ice  in ice- 
cold DPBS. Ice-cold Im m unoprec ip ia tion  bu ffe r (200 pi) (T ab le  3 .4) w as added to 
each well and the ce lls  w ere  scraped  and le ft in the buffer, on ice, fo r 15 m in. 
C ontents o f the trip licate  w e lls  w e re  scraped  and pooled in one sterile  
m icrocen trifuge  tube. The  lysed ce lls  w ere  passed 3-4  tim e s  though a 21 -g aug e  
needle. P rote in  A /G  beads (20 p i) (S anta  C ruz) w ere  added  to  the  cell lysate  and 
tubes w ere  p laced on a ro ta to r fo r  30 m in a t 4°C . Cell lysa tes w ere  then 
centrifuged at 10,000xg fo r 5 m in at 4°C. S uperna tan ts  w e re  co llected  into fresh  
tubes and pelle ts d iscarded. P ro te in  A /G  beads (20 pi) and 2 pg o f 
im m unoprec ip ita ting  antibody, o r 2 pg o f contro l IgG w ere  added to the  cell 
lysates, and ro tated o vern igh t a t 4 °C . The  im m uno co m plexe s w ere  co llected  by 
sp inning dow n the agarose  beads a t 10,000xg fo r 5 m in a t 4°C  and re ta in ing the  
pellet. Pellets w ere  w ashed  tw ice  in ice-co ld  0.5 ml im m unprec ip ita tion  buffer. 
Pelle ts  w ere resuspended in 30 pi SD S sam ple  b u ffe r fo r loading onto  gels. S D S - 
P AG E gels w ere  run and W este rn  b lo tting  w as carried o u t as in S ection  2.3.
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2.5 RNA Isolation, Preparation and Quantification
Cells (5 x 105/w e ll) w ere  g row n  and trea ted  in 6-w ell cu ltu re  p la tes, as in S ection 
2.2. Cells w ere  w ashed  w ith  ice-co ld  DPBS and 1 ml TRI R eagent w a s  added to 
each well and le ft fo r 5 m in. Lysates from  ind iv idual w e lls  w e re  then transfe rred  
to sterile , labelled m icrocen trifuge  tubes. C h lo ro form  (200 p i) w as added  to  each 
sam ple and sam ples w e re  shaken  fo r 15 sec, le ft to stand fo r 10 m in a t room  
tem p and then centrifuged  a t 12000xg fo r 15 m in a t 4°C . The  upper aqueous 
phase w as transfe rred  to new  labelled m icrocen trifuge  tub es  and 0.5 ml o f 
isopropanol w as added to each tube. The  sam ples w ere  m ixed severa l tim es by 
inversion, le ft to stand a t room  tem pe ra tu re  fo r  5-10 m in and cen trifuged  at 
12000xg fo r 5 m in a t 4°C. S uperna tan ts  w e re  d iscarded and the  R N A  pelle ts 
w ere w ashed tw ice  in 1 ml 75%  ethano l by vortex ing  and then  cen trifuga tion  at 
12000xg fo r 5 m in at 4°C. A ll e thanol w as then rem oved from  each tu b e  and the 
pelle ts w ere  a llow ed to d ry  in open tubes fo r a pp rox im a te ly  5 m in a t room  
tem pera ture  before  being resuspended in 50 pi nuc lease-free  S D W . R N A w as 
stored at -80°C . R NA concentra tion  and qua lity  w as dete rm ined  using the 
N anodrop 8000 S pectro ph o tom ete r (T herm o S cien tific ) as per the  m a n u fa c tu re r’s 
instructions.
2.6 cDNA Synthesis
cD N A w as syn thesised  from  1 pg RNA using the Q uan tiT ect R everse  
T ranscrip tion  K it (Q iagen) as per the  m a n u fa c tu re r’s instructions
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2.7 Quantitative-Real Time-PCR
Q uantita tive  R T-P C R  ana lys is  w as carried o u t on the  L igh tC yclerT M  1.0 (R oche, 
W est Sussex, UK) using fa s t start Taq DN A po lym erase  conta in ing  the  dou b le ­
stranded D NA b inding dye  S Y B R  G reen 1 from  the  Q u a n tiT e c t S Y B R  G reen 
PCR kit (Q iagen), accord ing  to the  m an u fa c tu re r’s instructions. P rim ers specific  
to HER2, M UC 4, M U C 5A C , M U C 5B o r G A PD H  o r p -actin  as norm alis ing  genes 
w ere  m anufactured  by E urofins (E bersberg , G erm any; p rim er sequences are 
show n in Tab le  3.5). The  sam ples w ere  d ena tu red  a t 95°C  fo r 15 m in fo llow ed  by 
35-40 cycles o f déna tu ra tion , annealing  and extens ion  at 95°C  fo r 15 sec, 55°C 
fo r 25 sec, and 72°C  fo r 11 sec (H E R 2, M U C 4, M U C 5A C , M U C 5B o r G APD H ), 
o r 95°C  fo r  15 sec, 55°C  fo r 20 sec, and 72°C  fo r 20 sec (p-actin). C haracte ris tic  
m elting curves w ere  obta ined  a t the  end o f am plifica tion  by cooling  the sam ples 
to 65°C fo r 15 se c  fo llow ed by fu rth e r coo ling  to 40°C  fo r 30 sec. Seria l 10-fold 
d ilu tions w ere  prepared from  ind ividual PC R  p roducts  purified  using the W izardR  
PCR Preps DN A P urifica tion  S ystem  (P rom ega, M ad ison, W l, USA), w h ich  w ere  
then used as s tandards  to p lo t aga ins t the unknow n sam ples. Q uantifica tion  o f 
data  w as ana lysed using the  L ightC yclerTM  ana lys is  so ftw are , and va lues w ere  
norm alised to the  level o f p-actin  o r G A PD H  express ion  fo r  each sam p le  on the 
sam e tem pla te  cD N A.
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2.8 Immunofluorescence
Growing and fixing cells: C e lls  (2 x1 0 5/w ell o f 12-well p la te) w ere  grow n and 
treated  on U V-sterilised covers lips  In 12-well cu ltu re  d ishes. C e lls  w ere  fixed  w ith  
3.7%  para fo rm a ldehyde  fo r 10 m inu tes at room  tem pera tu re  and incubated  in 
b locking bu ffe r (5%  w /v  norm al goa t serum , 0 .5%  v/v  T riton , in PBS) fo r 1 h at 
room  tem pera ture.
Humidity chamber: C ells w e re  sta ined in a tra y  w ith  a fo il covered base and lid. 
The base w as lined w ith  parafilm  and the inside lid lined w ith  m o is t tissue paper.
Cell staining: P rim ary and secondary  antibod ies w e re  d ilu ted  in b locking  b u ffe r at 
the  d ilu tions  show n in (Tab le  3.6). Fo llow ing b locking, covers lips  w ere  transfe rred  
face -dow n onto 80 pi d rops o f d ilu ted p rim ary a n tibo dy fo r  1 h at room  
tem pera ture, fo llow ed by th ree  5 m in w ashes in 80 pi d rops o f 1X PBS.
C overs lips  w ere  then transfe rred  in to  80 pi d rops o f d ilu ted  se condary  an tibody 
plus Phallo id in  (1 :1000) fo r 1 h a t room  tem pera ture , fo llow ed  by th ree  5 m in 
w ashes in 80 pi drops o f 1X PBS. N uclear s ta in ing  w a s  carried  out e ithe r w ith  
m ounting m edium  (V E C T A S H IE LD  Hard S et M ounting  M edium  w ith  DAPI,
V ecto r Labora tories, Inc.), o r in 80 pi drop o f DAPI (0 .5  pg /m l) a t room  
tem pera ture  fo r 10 m in, fo llow ed  by th ree  5 m in w ashes in 80 pi d rops o f 1X 
PBS. C overs lips w ere then  transfe rred  to labelled m icroscope  slides. If DAPI 
a lone w as used to  stain the  nuclei, the  covers lips  w e re  fixed  to  the  m icroscope  
s lides using c lear nail varn ish. S lides w ere  kept fla t fo r 24 h and stored a t 4°C  in 
the  dark until im aging on the  LSM 710 C onfoca l M icroscope.
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2.9 Si RNA Transfection
16H BE14o ce lls  w e re  serum -sta rved  o vern igh t p rio r to  transfec tion  w ith  s ilencing  
R NA (30 nM fina l concentra tion) aga ins t H ER 2, FAK, G A PD H  o r a non -sp ec ific  
negative contro l s ilencing  RN A (s iR N A ) (A pplied  B iosystem s) in se rum -free  
conditions, using T ra n s fa s t (P rom ega) accord ing  to the  m a nu fa c tu re r's  
instructions. C on tro ls  lacking siR N A  w e re  a lso  se t up. D ow n-regu la tion  o f the  
targe t genes w as confirm ed by W este rn  blotting.
2.10 Statistical Analysis
V alues are expressed as m ean ±S EM . Data w as eva lua ted  by tw o-ta ll s tud e n t’s 
t-test o r by A N O V A , as appropria te . T he  G raphpad Insta t p rogram  w a s used. A  
p-value o f 0 .05  o r less w as taken as s ign ificant.
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3. Tables
3.1 Cell Culture
Table 3.1.1 Fibronectin Coating Solution
LHC-8 basal medium 100ml
BSA 0.1 mg/ml
Collagen Type I 29 fjg/ml
Human Fibronectin 10 (jg/ml
Table 3.1.2 Growth Medium
MEM + Glutamax 500ml
Fetal Calf Serum 10% v/v
Penicillin/Streptomycin 0.5 U/ml
Table 3.1.3 Serum-Free Medium
MEM + Glutamax 500ml
Penicillin/Streptomycin 0.5 U/ml
Table 3.1.4 Cryofreezing Medium
Fetal Calf Serum 90% v/v
DMSO 10% v/v
3.2 Preparation of whole cell lysates in ‘Relax’ intracellular buffer
Table 3.2.1 Inhibitors
Inhibitor pretreatment time inhibits source
AG825 2h + removed Active HER2 Calbiochem
anti-CD29 2h + remains ß1 Integrin BD Pharmingen
PNGase F 1 h + removed N-linked glycosylation Calbiochem
Table 3.2.2 ‘Relax’ Intracellular Lysis Buffer
for 50ml final concentration
5ml 1M KCI 100mM KCI
150mI 1M NaCI 3mM NaCI
175^1 1M MgCI2 3.5mM MgCI2
500pi 1M HEPES pH 7.4 10mM HEPES pH7.4
add fresh on day of use
1X -Triton
1X protease inhibitors (Roche cat. no. 11836153001)
1X phosphatase inhibitors (Roche cat. no. 04906845001)
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3.3 Western Blotting
Table 3.3.1 Gel Composition
8% Separating Gel (1X) 4% Stacking Gel (1X)
37.5:1 Acrylamide: 
Bisacrylamide (Protogel 30%, 
Biosciences)
2.6 ml 500 pi
dH20 4.6 ml 2.25 ml
1.5M Tris (pH 8.8) 2.5 ml -
0.5M Tris (pH 6.8) - 950 Ml
10% SDS 200 Ml 38 Ml
10% APS 67 ul 25 i^i
TEMED 6.7 (Jl 3.8 Ml
Table 3.3.2 SDS Sample Treatment Buffer
0.5M Tris (pH 6.8) 2ml
10% SDS 2ml
0.1% Bromophenol blue 200mI
dH20 4ml
Glycerol 2ml
ß-mercaptoethanol 1m!
** not added when probing for ß1-lntegrin
Table 3.3.3 5X Running Buffer
Tris 0.12 M
Glycine 0.96 M
SDS 0.5% w/v
Table 3.3.4 1X Transfer Buffer
Tris 0.02 M
Glycine 0.15 M
SDS 0.01% w/v
Methanol 20% v/v
Table 3.3.5 10X TBS (pH 7.6)
Tris 0.2 M
NaCI 1.37 M
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Table 3.3.6 1X TBS-T {Wash Buffer)
Tris 0.02 M
NaCI 0.137 M
Tween-20 0.1% v/v
Table 3.3.7 Antibodies (for Western Blotting)
Antibody (all 
blocked in 5% 
Marvel/TBS-T
primary dilution secondary (all 
1:2000, all Santa 
Cruz)
primary antibody source
Active ß1-lntegrin 1:500 in 5% Marvel anti-mouse-HRP Millipore
pHER2 1:1000 in 5% BSA anti-rabbit-HRP Cell Signalling Technology
HER2 1:1000 In 5% BSA anti-rabbit-HRP Cell Signalling Technology
pFAK 1:200 in 5% Marvel anti-rabbit-HRP Santa Cruz
pERK 1:200 in 5% Marvel anti-rabbit-HRP Santa Cruz
ERK2 1:500 in 5% Marvel anti-rabbit-HRP Santa Cruz
3.4 Immunoprécipitation
Table 3.4 Immunoprécipitation Buffer
for 10ml final concentration
0.5ml Tris (pH 8.0) 50mM Tris, pH 8.0
0.3ml 5M NaCI 150mM NaCI
20yl 0.5M EDTA (pH 8.0) 1mM EDTA
100kJl Nonidet P-40 (IGEPAL) 1% Nonidet P-40 (IGEPAL) (v/v)
0.05g sodium deoxycholate 0.5% sodium deoxycholate
10gl 10% SDS 0.1% SDS (v/v)
Cocktail of protease inhibitors (Roche cat. no. 11836153001): 1 tablet/10 ml
Cocktail of phosphatase inhibitors (Roche cat. no. 04906845001): 1 tablet/10 ml
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3.5 Quantitative Real-Time PCR
Table 3.5 Primers
Primer Sequence melting
temperature
HER2 forward 5'-CAG CAG AGG ATG GAA CAC AG-3’ 59.4
HER2 reverse 5'-ACT CCT GGA TAT TGG CAC TG-3’ 57.3
MUC4 forward 5’-CTG TGT CTC TGC CTC CTT CC-3' 61.4
MUC4 reverse 5'-TTG TTG AGC CTG TTG AGG TG-3’ 57.3
p-actin forward 5'-GGA CTT CGA GCA AGA GAT GG-3’ 59.4
p-actin reverse 5’-AGG AAG GAA GGC TGG AAG AG-3' 59.4
GAP-DH forward 5’-CAA TGA CCC CTT CAT TGA CC-3’ 57.3
GAP-DH reverse 5’-GAC AAG CTT CCC GTT CTC AG-3’ 59.4
3.6. Immunofluorescence
Table 3.6.3 Antibodies (for Immunoflourescence)
Antibody dilution source
Integrin p i (JB1B) 1:80 Santa Cruz Biotech
goat anti-mouse IgG -  TR (texas red) 1:200 Santa Cruz Biotech
Phalloidin (Alexa Fluor 488) (green) 1:1000 invitrogen
1mg/ml mouse IgG 1:80 Sigma
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4. Results
4.1.1 EPO forms a complex with HER2 via N-linked glycosylation resulting 
in pHER2-dependent HER2 activation
To investigate if EPO forms a complex with the HER2 receptor, 16HBE14o cells 
were cultured (Section 2.1), harvested for immunoprécipitation (Section 2.2 and 
2.4) and subsequently analysed by Western blotting (Section 2.3). Samples were 
grown in triplicate in 6-well plates (1.5x106 cells/well) and treated. Samples 1-3 
were treated with 4 pg/ml EPO for 18 h and samples 4-6 were left untreated for 
the same length of time. Each of the 6 samples were then immunoprecipitated 
with an individual specific antibody or with a species-specific IgG control, as 
indicated in the table in Figure 1, and all were probed with an anti-EPO antibody 
to see which receptor, if any, bound EPO. Figure 1 shows a band in lane 1 at the 
expected size for a complex between EPO and the HER2 receptor. Lane 1 was 
treated with EPO for 18 h, immunoprecipitated with an anti-HER2 antibody and 
then probed with an anti-EPO antibody. By contrast, no band was observed in 
lane 2, in which the EPO-treated sample was immunoprecipitated with an anti- 
HER1 antibody, or in lane 3 in which the EPO-treated sample was 
immunoprecipitated with an IgG control. This suggests that that the complex 
formed by EPO and HER2 is specific, and is in keeping with previous results 
regarding the specific effect of EPO on HER2 expression. As a control, the 
untreated samples in the absence of EPO show no evidence of complex 
formation whether they are immunoprecipitated with anti-HER2, anti-HER1 or 
IgG. This experiment was performed twice.
4.1 Results Chapter One - EPO induced HER2 activation
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1 2 3 4 5 6
Lane Immuno
-precipitated
with
T reatment: 
EPO (4pg/ml, 
18h)/untreated
1 anti-HER2 EPO
2 anti-HER1 EPO
3 IgG EPO
4 anti-HER2 untreated
5 anti-HER1 untreated
6 IgG untreated
Figure 1. EPO complexes with HER2 and not with HER1. 16HBE14o cells were treated 
with EPO (4 jjg/ml, 18 h) (lanes 1-3) or left untreated (lanes 4-6). Cells were 
immunoprecipitated with an anti-HER2, anti-HER1 (ISIS, Ltd., Wicklow) or IgG control 
(Fannin Healthcare, Dublin) antibody and the resulting Western Blot was probed with a 
goat anti-human EPO antibody (Santa Cruz).
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The next question was whether this interaction between EPO and HER2 also 
leads to the activation of the HER2 receptor. As before, 16HBE14o cells were 
treated with 4 pg/ml Eosinophil peroxidase at 4 and 18 h, harvested in ‘Relax’ 
Lysis Buffer and analysed by Western Blotting. The blot was probed with a p- 
Y1248-HER2 antibody (Figure 2), specific to HER2 auto-phosphorylated at the 
Y1248 site. A time-dependent increase in HER2 phosphorylation was observed 
in response to EPO at site Y1248, indicated by the bands at approximately 185 
kDa (Figure 2, top panel). Blots were stripped and re-probed for ERK2 as a 
loading control (Figure 2, bottom panel). This experiment was performed three 
times.
This next experiment aimed to understand the nature of the interaction between 
EPO and HER2. There is no known soluble ligand for HER and HER2 is heavily 
glycosylated so we next investigated whether the interaction between EPO and 
HER2 was dependent on the glycosylation of HER2. It was found that the 
interaction between EPO and HER2 is mediated via N-linked glycosylation 
(Figure 3). 16HBE14o cells were treated with 4 pg/ml EPO at 4 and 18 h, in the 
presence of PNGaseF pre-treatment (2U/ml, 3h, inhibitor of N-linked 
glycosylation), harvested in ‘Relax’ Lysis Buffer and analysed by Western 
Blotting. The blot was probed with a p-Y1248-HER2 antibody, specific to HER2 
auto-phosphorylated at the Y1248 site. No increase in HER2 phosphorylation 
was observed in response to EPO at site Y1248, indicated by the bands at 
approximately 185 kDa (Figure 3, top panel). Blots were stripped and re-probed 
for ERK2 as a loading control (Figure 3, bottom panel). This experiment was 
performed twice.
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pHER2 expression in response 
to EPO treatment
—  — H p H ER2
ERK2
EPO (4pg/ml)
Figure 2. EPO induces the phosphorylation of HER2. Western blots of 16HBE14o 
protein (60(jg) from cells treated with EPO (4pg/ml) for the indicated timepoints, were 
probed with an anti-pHER2 antibody (ISIS Ltd., Wicklow) (top panel) and an ERK2 antibody 
(Fannin Healthcare, Dublin) (bottom panel) for normalisation. The graph show the fold 
change in pHER2 expression levels in response to EPO treatment compared to untreated 
cells at the indicated times. (n=3, mean ± sem; **p<0.01, ***p<0.001)
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pHER2 expression in response
to EPO treatment with PNGaseF
EPO (4pg/ml)
Figure 3. EPO-induced phosphorylation of HER2 is dependent on N-linked
glycosylation. Western blots of 16HBE14o protein (60^g) from cells treated with EPO 
(4|jg/ml) for the indicated timepoints, in the presence of PNGase F pretreatment (2U/ml, 1 h; 
inhibitor of N-linked glycosylation) (Sigma Aldrich, Dublin), were probed with an anti-pHER2 
antibody (ISIS Ltd., Wicklow) (top panel) and an ERK2 antibody (Fannin Healthcare, 
Dublin) (bottom panel) for normalisation. The graph show the fold change in pHER2 
expression levels in response to EPO treatment compared to untreated cells in the 
presence of PNGaseF at the indicated times. (n=2)
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We next investigated the effect of EPO treatment on the transcriptional levels of 
total HER2 receptor. Cells were harvested in TRI Reagent and RNA was 
extracted from the samples (Section 2.5), cDNA was synthesised (Section 2.6) 
and Quantitative Real-Time PCR (Section 2.7) was performed to determine the 
HER2 receptor expression levels in response to EPO at 4 and 18 h and found 
that EPO induced an increase in HER2 mRNA levels (Figure 4A). In order to 
determine an order of events, we pre-treated some cells with AG825 (10 uM, 2 h; 
inhibitor of HER2 tyrosine kinase activity) and found that the EPO-induced 
increase in total HER2 receptor mRNA expression was dependent on the initial 
phosphorylation of the HER2 receptor (Figure 4B) as there was no increase in 
HER2 gene expression in response to EPO in the presence of AG825.
The experiments in Figure 4 have been performed twice.
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Figure 4. EPO induces a pHER2-dependent increase in the transcriptional levels of 
total HER2. 16HBE14o cells were treated with EPO (4pg/ml) in the absence (A) or 
presence (B) of AG825 pre-treatment (10 pM, 2 h; inhibitor of HER2 tyrosine kinase 
activity) and harvested for cDNA synthesis. Real-Time PCR graph show the fold change in 
HER2 relative to p-actin expression in response to EPO (4 pg/ml) at the indicated 
timepoints, versus untreated cells (n=2)
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Our next experiment was designed to investigate if there was an increase in the 
total HER2 protein levels in response to EPO treatment and to determine its 
dependence on the tyrosine kinase activity of HER2. Again 16HBE14o cells were 
treated with 4 pg/ml EPO at 4 and 18 h, in the absence (Figure 5) or presence 
(Figure 6) of 10pM AG825. Cells were harvested in ‘Relax’ Lysis Buffer (Section
2.2) and analysed by Western Blotting (Section 2.3). The membranes were 
probed with a HER2 antibody and the results show that EPO induces a modest 
increase in HER2 expression (Figure 5) which was sensitive to AG825-mediated 
inhibition of HER2 tyrosine kinase activity (Figure 6). The experiments in Figure 5 
have been performed three times and the experiments in Figure 6 have been 
performed twice.
We have previously shown that the EPO-induced phosphorylation of HER2 is 
dependent on N-linked glycosylation, and so, this next experiment aimed to show 
the importance of N-linked glycosylation on EPO-induced increase in total HER2 
protein receptor expression. 16HBE14o cells were treated with 4pg/ml EPO at 4 
and 18 h, in the presence of PNGaseF pre-treatment (2 U/ml, 3 h, inhibitor of N- 
linked glycosylation), harvested in ‘Relax’ Lysis Buffer and analysed by Western 
Blotting. The blot was probed with an antibody specific to HER2. No increase in 
total HER2 protein level was observed in response to EPO, indicated by the 
bands at approximately 185 kDa (Figure 7, top panel). Membranes were stripped 
and re-probed for ERK2 as a loading control (Figure 7, bottom panel). This 
experiment has been performed twice.
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HER2 expression in responseto EPO treatment
HER2
ERK2
EPO (4pg/ml)
Figure 5. EPO induces an increase in total HER2 receptor protein expression.
Western blots of 16HBE 14o protein (60yg) from cells treated with or without EPO (4pg/ml) 
at the indicated times, were probed with an anti-HER2 antibody (ISIS Ltd., Wicklow) (top 
panel) and an ERK2 antibody (Fannin Healthcare, Dublin) (bottom panel) for normalisation. 
The graph show the fold change in HER2 expression levels in response to EPO treatment 
compared to untreated cells at the indicated times. (n=3, mean ± sem; *p<0.05, **p<0.01, 
***p<0.001). The blots shown are representative of 3 similar experiments
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HER2 expression in responseto EPO treatment with AG825
EPO (4pg/ml)
Figure 6. EPO-induced increase in HER2 protein expression is dependent on the 
initial phosphorylation of HER2. Western blot of 16HBE 14o protein (60|jg) from cells 
treated with or without EPO (4pg/ml) at the indicated times, in the presence of AG825 
pretreatment (lOpM, 2h) were probed with an anti-HER2 antibody (top panel) and an ERK2 
antibody (bottom panel) for normalisation. The graph show the fold change in HER2 
expression levels in response to EPO treatment compared to untreated cells in the 
absence (C) or presence (D, E) of inhibitors at the indicated times. (n=2). The blots shown 
are representative of 2 similar experiments.
42
HER2 expression in response
to EPO treatment with PNGaseF
CN
O' 2.5 -i
c S j 2.0 •
OJ "c 
“ .2 1.5 -
<3 </>
O £  1.0 i
2  x
o  0) 0.5 ■
0.0
ERK2
HER2
i i i l
p * '
EPO (4pg/ml)
Figure 7. EPO-induced pHER2-dependent increase in HER2 protein expression is 
dependent on N-linked glycosylation. Western blot of 16HBE 14o protein (60 ^ig) from 
cells treated with or without EPO (4 pg/ml) at the indicated times, in the presence of 
PNGase F pre-treatment (2 U/ml, 2h), were probed with an anti-HER2 antibody (ISIS Ltd.,
Wicklow) (top panel) and an ERK2 antibody (Fannin Healthcare, Dublin) (bottom panel) for 
normalisation. The graph show the fold change in HER2 expression levels In response to 
EPO treatment compared to untreated cells in the presence of PNGaseF at the indicated 
times. (n=2). The blots shown are representative of 2 similar experiments.
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4.1.2 Specificity of EPO-HER2 relationship
To confirm the specificity of the EPO-HER2 relationship, we next investigated the 
effect of EPO on HER1 (another EGFR Family member). 16HBE140 cells were 
treated at the indicated times with EPO (4 pg/ml) and harvested in TRI Reagent. 
RNA was extracted from the samples, cDNA was synthesised and Quantitative 
Real-Time PCR was performed to determine the HER1 receptor expression 
levels in response to EPO at 1, 4,18 and 24 h. We found that EPO treatment 
had no effect on HER1 mRNA levels (Figure 8).
HER1 expression in 
response to EPO treatment
5 ~\
EPO (4pg/ml)
Figure 8. EPO treatment has no effect on the transcriptional expression of HER1.
16HBE14o cells were treated with EPO (4 (jg/ml) at the indicated timepoints, and harvested 
for cDNA synthesis. Real-Time PCR graph shows the fold change in HER1 relative to p- 
actin expression in response to EPO (4 pg/ml) at the indicated timepoints, versus untreated 
cells (n=3).
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Another experiment to test the EPO-HER2 specificity was performed, this time to 
determine the granule protein specificity towards the HER2 receptor. This time, 
16HBE14o cells were treated with MBP (4ug/ml) and harvested in TRI Reagent. 
RNA was extracted from the samples, cDNA was synthesised and Quantitative 
Real-Time PCR was carried out to determine the HER2 receptor expression 
levels in response to MBP at 1, 4, 18 and 24 h. We found that MBP treatment 
had no effect on HER2 mRNA levels (Figure 9).
HER2 expression in response 
to MBP treatment
MBP treatment
Figure 9. MBP treatment has no effect on the transcriptional expression of HER2.
16HBE14o cells were treated with MBP (4pg/ml) at the indicated timepoints, and harvested 
for cDNA synthesis. Real-Time PCR graph shows the fold change in HER2 relative to p- 
actin expression in response to MBP (4pg/mi) at the indicated timepoints, versus untreated 
cells (n=3).
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4.2 Results Chapter Two - EPO-induced (31 integrin activation
4.2.1 EPO induces activation of ¡51 integrin
To determine if EPO-induced HER2 activation had further consequences for 
bronchial epithelial cells, we examined pi-integrin activation in response to EPO 
treatment. Section 1.4.6 in the introduction highlights the research to date behind 
the interactions of integrins and growth factor receptors and so gives a good 
explanation for our next experiment choice. 16HBE14o cells were cultured 
(Section 2.1), fixed and immunofluorescently stained (Section 2.8) for imaging 
using the LSM710 Confocal Microscope. Cells were treated with 4 pg/ml EPO for 
4 and 18 h. Once fixed, cells were stained using a mouse anti-human CD29 
antibody to stain for p1 Integrin with an anti-mouse secondary antibody 
conjugated to Alexa 633 (far-red). Alexa Phalloidin (Alexa 488-green) was used 
with the secondary antibody to stain for F-actin and DAPI to stain for the nuclei 
(blue). Figure 10 shows a distinct clustering of pi integrin (red) after 18 h 
treatment with EPO (Figure 10C). In this image there is also a significant change 
in the structure of F-actin (green). This clustering of pi Integrin, co-localised with 
F-actin (seen as orange clusters) indicated that EPO induced activation of pi 
Integrin. After 4 h of treatment with EPO there was some clustering of p i Integrin 
visible (Figure 10B), but this was significantly more extensive by 18 h (Figure 
10C). These confocal microscopy results were confirmed by Western Blotting 
(Figure 10E and F). An IgG control well was setup to rule out any non-specific 
binding. 16HBE14o cells were treated with 4 pg/ml EPO for 4 and 18 h, 
harvested in ‘Relax’ Lysis Buffer (Section 2.2) and analysed by Western Blotting 
(Section 2.3). The blots were probed with an antibody specific to the active form 
of p i integrin (Millipore), and in Figure 10E increased density of the band at 88 
kDa indicated an increase in the levels of active p i integrin at 4 and 18 h. The 
graph in Figure 10E represents the densitometry data for active p1 integrin in two 
experiments compared to ERK2.
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To confirm the specificity of the observations, cells were pre-treated with a 
neutralising anti-CD29 antibody against p i integrin prior to EPO treatment. In the 
presence of pre-treatment with anti-CD29, there was a significant reduction in 
clustering of pi integrin (red) and |31 integrin co-localisation with F-actin 
(orange/yellow) (Figure 10D). These results demonstrated the specificity of the 
anti-CD29 inhibitor and also confirmed that the red clusters seen in the confocal 
microscopy pictures (Figure 10B and C) are active p i integrin. These results 
were again confirmed by Western Blotting against an antibody specific to active 
pi-integrin (Figure 10F). In the presence of anti-CD29 there is no up-regulation 
in the activation of pi-integrin. The graph in Figure 10F represents the 
densitometry data for active p i integrin in two experiments compared to ERK2. 
There was no EPO-induced up-regulation of active pi-integrin following anti- 
CD29 pre-treatment. The confocal microscopy experiments in Figure 10 were 
preformed three times. The Western Blots in Figure 10E and F are n=2.
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untreated B 4 hour EPO
C 18 h ou r EPO
18 h ou r EPO  
+ an ti-C D 29
A ctive p i  in tegrin  expression  in 
response to  EPO  treatm en t
F slS A ctive  p i in tegrin  express ion  in 
response to  EPO  trea tm en t 
w ith  an ti-C D 29
EPO  (4jjg /m l) EPO  (4pg /m l)
F ig u re  10 . E P O  in d u c e s  th e  a c tiv a tio n  o f  p i In te g r in . (A-D) 16HBE14o cells were grown 
on coverslips and left untreated (A) or treated (B-D) with EPO (4 pg/ml) for the indicated 
times. Some were pretreated with anti-CD29 (1 pg/ml, 2 h; specific anti-p1 integrin 
neutralising antibody) (BD Biosciences, Oxford) (D). Western blotting of 16HBE140 protein 
(30 pg) from cells treated with or without EPO (4 pg/ml) for the indicated times in the 
absence of inhibitor (E), or the presence of anti-CD29 antibody (1 pg/ml, 2h) (F) were 
probed with antibody to active p1-integrin (Millipore Ireland) and against ERK2 for 
normalisation. The graphs show the fold change in active p i integrin expression levels in 
response to EPO treatment compared to untreated cells in the absence (E) or presence (F) 
of anti-CD29 at the indicated times. (n=2).
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4.2.2 EPO-induced activation of pi integrin is dependent on HER2 tyrosine 
kinase activity
The next set of experiments investigates the association between integrin 
activation and HER2 receptor activation (Figure 11). A new staining antibody for 
pi integrin (JB1B) was used in these experiments; this was to confirm integrin 
clustering with another antibody, with a view to inhibit this clustering with the 
original anti-CD29 antibody and to eliminate any effect of using the same 
antibody for staining and inhibiting within the same experiment. JB1B is a mouse 
monoclonal antibody raised against integrin pi of human origin. 16HBE14o cells 
were cultured (Section 2.1), fixed and immunofluorescently stained (Section 2.8) 
for imaging using the LSM710 Confocal Microscope. Cells were treated with 4 
pg/ml EPOfor 18 h (Figure 11A and B) and the cells in Figure 11B were 
pretreated with AG825, an inhibitor of HER2 tyrosine kinase activity. Once fixed, 
cells were stained using the JB1B antibody to stain for p1 Integrin, with a goat- 
anti-mouse IgG Texas-Red secondary antibody. Alexa Phalloidin (Alexa 488- 
green) was used with the secondary antibody to stain for F-actin and DAPI to 
stain for the nuclei (blue). Figure 11A shows a distinct activation of p i Integrin 
with co-localisation to F-actin (orange staining) after 18 h treatment with EPO. 
Pre-treatment of cells with AG825 prior to EPO treatment inhibited this co­
localisation (Figure 11B), indicating that the presence of AG825 pre-treatment 
inhibits the EPO-induced activation of pi-integrin. These results were confirmed 
by Western blotting using an active pi-integrin specific antibody (Figure 110) 
where no increase in the activation of pi-integrin is seen in response to EPO in 
the presence of AG825. The graph in Figure 110 represents the densitometry 
data for active pi integrin in two experiments compared to ERK2.
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16HBE14o cells were grown on coverslips and treated with EPO (18 h, 4 |jg/ml) (A,B). 
Some were pretreated with AG825 (10 (jM, 2h) (B). Western blotting of 16HBE140 protein 
(30 pg) from cells treated with or without EPO (4 pg/ml) for the indicated times in the 
presence (black bars) or absence (gray bars) of AG825 (10 pM, 2h) (C) were probed with 
antibody to active pi-integrin (Millipore Ireland) (top panels) and against ERK2 (bottom 
panels) for normalisation. The graph show the fold change in active p i integrin expression 
levels in response to EPO treatment compared to untreated cells in the presence or 
absence of AG825 at the indicated times. (n=2).
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4.2.3 Importance of pi integrin
Having shown that EPO binds to HER2, activating both HER2 and p i integrin 
and upregulating HER2 at both a gene and protein level, we needed to assess 
the order in which these events occur. This next experiment investigated the 
effects of inhibited pi-integrin activation on the EPO-induced upregulation of total 
HER2 protein (Figure 12). 16HBE14o cells were treated with 4 pg/ml EPO at 4 
and 18 h, in the presence of 1 pg/ml anti-CD29. Cells were harvested in ‘Relax’ 
Lysis Buffer and analysed by Western Blotting. The membranes were probed 
with a HER2 antibody and the results show that an increase in EPO-induced total 
HER2 protein is still seen in the presence of the inhibitor, indicating a non­
dependence of EPO-induced HER2 on activation of pi-integrin. The graph in 
Figure 12 shows densitometry results of two Western Blots normalized against 
ERK2.
This result now shows a clear direction of EPO-induced HER signalling. EPO first 
engages HER2, leading to the activation of HER2. EPO-induces activation of pi 
integrin (Figure 10) but the EPO-induced increase in HER2 protein expression is 
independent of p i integrin activation.
51
HER2 expression in response
to EPO treatment +/- anti-CD29
no inhibitor 
+ anti-CD29
EPO (4pg/ml)
F ig u re  12. E P O -in d u c e d  a c tiv a tio n  o f  H E R 2  is in d e p e n d e n t o f  p i  in te g rin  a c tiv a tio n .
Western blots of 16HBE 14o protein (60pg) from cells treated with or without EPO (4pg/ml) 
at the indicated times, in the absence (white bars) or presence (black bars) of anti-CD29 
pretreatment (1pg/ml, 2h), were probed with anti-HER2 antibody. The graph shows the fold 
change in HER2 expression levels in response to EPO treatment compared to untreated 
cells in the absence or presence of anti-CD29 at the indicated times. (n=2)
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4.3 Results Chapter Three - EPO-induced downstream signalling
4.3.1 EPO-induces a HER2-, pi integrin-, N-linked glycosylation-dependent 
activation of FAK.
The next set of experiments looked at the effect of EPO on the activation of FAK. 
In a proteomic screen performed with the IMR32 nerve cell line previously in the 
lab, it was observed that FAK is commonly activated in response to growth factor 
receptor signalling and in response to integrin activation. 16HBE14o cells were 
treated with 4 pg/ml EPO at 4 and 18 h. Cells were harvested in ‘Relax’ Lysis 
Buffer and analysed by Western Blotting. The membranes were probed with an 
antibody specific to p-Y397-FAK and the results show an EPO-induced increase 
in the levels of p-Y397-FAK (125kDa) in a time-dependent manner. The graph in 
Figure 12 shows densitometry results of 3 Western Blots normalised against 
ERK2.
In order to determine the mechanism of EPO-induced FAK activation, the cells 
were pre-treated with various inhibitors in the next set of experiment. In Figure 
14, 16HBE14o cells were pretreated with AG825 (10 uM, 2 h) and the resulting 
Western Blot shows no increase in the levels of pFAK in response to EPO in the 
presence of inhibitor, indicating that EPO activates FAK via HER2.
In Figure 15, 16HBE140 cells were pretreated with anti-CD29 (1ug/ml, 2 h) and 
the resulting Western Blot shows no increase in the levels of pFAK in response 
to EPO in the presence of the CD29 inhibitor, indicating that the EPO-induced 
activation of FAK is also dependent on the activation of the pi integrin. Integrins 
and Growth Factor Receptors interact to activate FAK and MAP Kinase proteins 
further downstream. Hence, this result shows that for EPO to induce activation of 
FAK via HER2, p i integrin must also be active.
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In Figure 16, 16HBE140 cells were pretreated with PNGase F (1 U/ml, 2h) and 
the resulting Western Blot shows no increase in the levels of pFAK in response 
to EPO in the presence of inhibitor, indicating that the EPO-induced activation of 
FAK is mediated through HER2 via N-linked glycosylation.
The Western Blots including pretreatment with inhibitors, (Figures 14, 15 and 16) 
have been performed twice. The uninhibited experiment in Figure 13 has been 
performed three times.
pFAK expression in response 
to EPO treatment
pFAK
ERK2
EPO (4pg/ml)
Figure 13. EPO induces phosphorylation of FAK
Western blots of 16HBE 14o protein (30^ig) from cells treated with or without EPO (4 Mg/ml) 
at the indicated times were probed with an anti-pFAK antibody (Fannin Healthcare, Dublin). 
The graph shows the fold change in pFAK expression levels in response to EPO treatment 
compared to untreated cells at the indicated times. (n=3, mean ± sem; *p<0.05, **p<0.01, 
***p -0.001). The blots shown are representative of 3 similar experiments. The levels of 
total FAK remain the same with all treatments (data not shown).
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Figure 14. EPO-induced activation of FAK is dependent on the initial 
phosphorylation of HER2. Western blots of 16HBE 14o protein (30 ^g) from cells treated 
with or without EPO (4 pg/ml) at the indicated times, in the presence of AG825 (10 j jM , 2h) 
were probed with an anti-pFAK antibody (Fannin Healthcare, Dublin). The graph show the 
fold change in pFAK expression levels in response to EPO treatment compared to 
untreated cells in the presence of inhibitor at the indicated times. (n=2). The blots shown 
are representative of 2 similar experiments. The levels of total FAK remain the same with 
all treatments (data not shown).
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Figure 15. EPO-induced activation of FAK is dependent on the activation of 01- 
integrin. Western blots of 16HBE 14o protein (30 pg) from cells treated with or without 
EPO (4 pg/ml) at the indicated times, in the presence of anti-CD29 (1 ^gAnl, 2 h) were 
probed with an anti-pFAK antibody (Fannin Healthcare, Dublin). The graph show the fold 
change in pFAK expression levels in response to EPO treatment compared to untreated 
cells in the presence of inhibitor at the indicated times. (n=2). The blots shown are 
representative of 2 similar experiments. The levels of total FAK remain the same with all 
treatments (data not shown).
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Figure 16. EPO-induced activation of FAK is dependent on N-linked glycosylation.
Western blots of 16HBE 14o protein (30 jjg) from cells treated with or without EPO (4pg/ml) 
at the indicated times, in the presence of PNGase F (2 U/ml, 1h) were probed with an anti- 
pFAK antibody (Fannin Healthcare, Dublin). The graph show the fold change in pFAK 
expression levels in response to EPO treatment compared to untreated cells in the 
presence of inhibitor at the indicated times. (n=2). The blots shown are representative of 2 
similar experiments. The levels of total FAK remain the same with all treatments (data not 
shown).
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4.3.2 EPO-induced ERK phosphorylation is dependent on N-linked 
glycosylation, independent of HER2 tyrosine kinase activity and delayed in 
the absence of pi integrin activation
The next set of experiments investigated the effect of EPO on the activation of 
ERK. In the previously mentioned proteomic screen, pERK levels increased 
significantly in response to 18 h EPO treatment. ERK is a member of the MAP 
Kinase signalling cascade and is commonly activated by growth factor receptors. 
16HBE14o cells were treated with 4|jg/ml EPO at 4 and 18 h, Cells were 
harvested in ‘Relax’ Lysis Buffer and analysed by Western Blotting. The 
membranes were probed with a pERK antibody and the results show an EPO- 
induced increase in the levels of p-ERK (42/44kDa) in a time-dependent manner 
(Figure 17). The graph in Figure 17 shows densitometry results of 3 Western 
Blots normalised against ERK2.
In order to determine the mechanism of EPO-induced ERK activation and its 
position in this EPO-induced cell signalling cascade, the cells were pretreated 
with various inhibitors in the next set of experiments.
In Figure 18, 16HBE140 cells were pretreated with AG825 (10uM, 2h) and the 
resulting Western Blot still shows an increase in the levels of pERK in response 
to EPO in the presence of inhibitor, indicating that EPO activates ERK 
independently of HER2 tyrosine kinase activity.
In Figure 19, 16HBE140 cells were pre-treated with anti-CD29 (1ug/ml, 2h) and 
the resulting Western Blot still shows a delayed increase in the levels of pERK in 
response to EPO in the presence of inhibitor, indicating that the early EPO- 
induced activation of ERK is dependent on pi integrin activation, but by 1 h EPO 
treatment, the phosphorylation of ERK does occur.
58
In Figure 20, 16HBE140 cells were pretreated with PNGase F (1 U/ml, 2 h) and 
the resulting Western Blot shows no increase in the levels of pERK in response 
to EPO in the presence of inhibitor, indicating that the EPO-induced activation of 
ERK is mediated via N-linked glycosylation.
pERK expression in response 
to EPO treatment
EPO (4pg/ml)
Figure 17. EPO induces the activation of ERK. Western blots of 16HBE 14o protein (30 
pig) from cells treated with or without EPO (4pg/ml) at the indicated times, were probed with 
an anti-pERK antibody (Fannin Healthcare, Dublin). The graph show the fold change in 
pERK expression levels in response to EPO treatment compared to untreated cells at the 
indicated times. (n=3, mean ± sem; *p<0.05, **p<0.01, ***p<0.001).
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Figure 18. EPO-induced activation of ERK is independent of the tyrosine kinase 
activity of HER2. Western blots of 16HBE 14o protein (30(jg) from cells treated with or 
without EPO (4pg/ml) at the indicated times, in the presence of AG825 (IO^iM, 2 h), were 
probed with an anti-pERK antibody (Fannin Healthcare, Dublin). The graph show the fold 
change in pERK expression levels in response to EPO treatment compared to untreated 
cells in the presence of inhibitor at the indicated times. (n=2). The blots shown are 
representative of 2 similar experiments.
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Figure 19. EPO-induced activation of ERK is delayed in the absence of pi integrin 
activation. Western blots of 16HBE 14o protein (30 pg) from cells treated with or without 
EPO (4pg/ml) at the indicated times, in the presence of anti-CD29 (1 pg/ml, 2 h) were 
probed with an anti-pERK antibody (Fannin Healthcare, Dublin). The graph show the fold 
change in pERK expression levels in response to EPO treatment compared to untreated 
cells in the presence of inhibitor at the indicated times. (n=1).
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Figure 20. EPO-induced activation of ERK is dependent on N-linked glycosylation.
Western blots of 16HBE 14o protein (30 (jg) from cells treated with or without EPO (4pg/ml) 
at the indicated times, in the presence of PNGase F (2U/ml, 1h) were probed with an anti- 
pERK antibody (Fannin Healthcare, Dublin). The graph show the fold change in pERK 
expression levels in response to EPO treatment compared to untreated cells in the 
presence of inhibitor at the indicated times. (n=3). The blots shown are representative of 3 
similar experiments.
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4.3.3. Role of FAK activation in EPO-induced downstream signalling
EPO induces the activation of the HER2 receptor and activation of (31 integrin 
with consequent FAK and ERK activation. We next investigated the effect of 
inhibiting FAK or HER2, on the EPO-induced HER2, p1 integrin and ERK 
activation. 16HBE14o cells were transfected with silencing RNA (30 nM final 
concentration) against HER2, FAK, GAPDH or a non-specific negative control 
silencing RNA (siRNA) (Section 2.9). Controls lacking siRNA were also set up. 
Down-regulation of the target genes was confirmed by Western blotting. Results 
show that both HER2 and FAK silencing reduce activation of p i integrin and 
ERK. FAK silencing does not reduce EPO-induced up-regulation of HER2. These 
results give a definite order of events post EPO treatment.
+ EPO (4|jg/ml)
T ransfast
siRNA
on|y Neg HER2 FAK GAPDH
HER2 
pFAK
p i  integrin
pERK
ERK2
Figure 21. EPO-induced p i integrin activation is dependent on FAK and HER2. Western 
blots of 16HBE14o protein (60 (jg for HER2; 20 (jg for FAK, pFAK, (31 integrin, ERK2, 
GAPDH) from cells grown in the absence or presence of EPO (4 ^ig/ml, 18 h) as indicated.
Cells were transfected or not, as indicated, with silencing RNA to a scrambled negative 
control (siNeg), HER2 (siHER2), FAK (siFAK) or GAPDH (siGAPDH). The blots shown are 
representative of 2 similar experiments.
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4.3.4. Mucin gene expression
MUC4 is a tethered ligand for HER2 influencing its activation. We have shown by 
qRT-PCR that EPO induces an upregulation in the transcriptional expression of 
MUC4 at 4 and 18 h EPO treatment (Figure 22, gray bars). We have also shown 
that in the presence of AG825, the levels of MUC4 do not increase in response to 
EPO treatment (Figure 22, black bars), indicating that this EPO-induced 
upregulation in MUC4 gene expression is dependent on the initial activation of 
the HER2 receptor.
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Figure 22. EPO induces a HER2-dependent increase in the transcriptional expression 
of MUC4. 16HBE14o cells were treated with EPO (4(jg/ml) in the absence (gray bars) or 
presence (black bars) of AG825 pre-treatment (10pM, 2h; inhibitor of HER2 tyrosine kinase 
activity) and harvested for cDNA synthesis. Real-Time PCR graph show the fold change in 
MUC4 relative to p-actin expression in response to EPO (4pg/ml) at the indicated 
timepoints, versus untreated cells (n=2).
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5. Conclusion
This thesis provides evidence that eosinophil peroxidase (EPO) forms a complex 
with the HER2 receptor. We have shown that EPO treatment results in the 
phosphorylation of the HER2 receptor and also in the increase in total HER2 
receptor protein expression levels. We have shown that the increase in total 
HER2 protein levels is dependent on the initial phosphorylation / activation of the 
HER2 receptor by EPO. We have shown that the EPO-induced increase in both 
pHER2 and HER2 protein expression is mediated via N-linked glycosylation. The 
HER2 molecule is heavily glycosylated, hence this may be the mechanism of 
interaction between it and the EPO molecule. This is the first description of a 
soluble ligand for HER2 and it is the first description of a receptor for an 
eosinophil protein.
We have shown certain specificity between EPO and HER2 by 
investigating other EGF receptors and eosinophil granule proteins. We found that 
EPO does not form a complex with HER1 and EPO does not have any affect on 
the transcriptional levels of HER1. We also found that Major Basic Protein 
(another eosinophil granule protein), had no effect on the transcriptional levels of 
HER2.
Results in this thesis also provide evidence that EPO induces the 
activation of pi integrin. It is likely that EPO induced activation of HER2 directly 
mediates [31 integrin activation. This EPO-induced activation of p i integrin is 
dependent on the initial activation of the HER2 receptor since p i integrin 
activation is inhibited by HER2 inhibition. Furthermore, EPO lacks a RGD (Arg- 
Gly-Asp) sequence which is typical of integrin ligands. In support also of the 
result that EPO activates pi integrin is the observation that EPO induced *he 
activation of Focal Adhesion Kinase (FAK), via HER2 tyrosine kinase activation. 
Similarly, silencing of FAK, results in pi integrin no longer being activated by 
EPO. Since FAK forms part of a complex of scaffold proteins, which mediate
65
inside out signalling of integrins, these data suggest that there is a series of 
consequences that follow HER2 activation by EPO. The formation of this scaffold 
is important for activation of pi integrin, for interaction with the HER2 receptor 
and potentially for activation of further downstream signalling molecules, for 
example ERK MAP Kinase signalling.
We next investigated potential downstream consequences of EPO- 
induced cell signalling and found that Extracellular Signal Regulated Kinase 
(ERK) is activated by EPO. This is a confirmation of our prior observations in 
IMR32 nerve cells. We have shown that EPO induces thb activation of ERK, via 
N-linked glycosylation. ERK phosphorylation still occurs when we inhibit the 
tyrosine kinase activity of HER2, suggesting that ERK activation can still be 
induced by other pathways. Inhibition of pi integrin activation (investigated by
Diagram  10. Order of activation post 
EPO-HER2 complex formation.
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chemical inhibition) delays ERK activation (again suggesting the involvement of 
other pathways). These other pathways are still activating ERK in response to 
EPO via N-linked glycosylation, but perhaps through proteins associated with 
HER2, for example MUC4, HER1, 3 or 4. ERK could potentially be activated 
through one of these proteins even when the tyrosine kinase activity of HER2 is 
inhibited. When HER2 is silenced, however, we see little activation of ERK. The 
effect of silencing HER2 relative to chemically inhibiting its tyrosine kinase 
activity, may affect the ability of HER2 to interact with other vital proteins involved 
in cell signalling, therefore explaining the conflicting results between silencing 
HER2 and inhibiting its tyrosine kinase activity, on EPO-induced ERK activation.
Further downstream, we have shown that EPO induces an increase in the 
transcriptional expression of the mucin gene MUC4. The EPO-induced activation 
of ERK was independent of HER2 activation (investigated by chemical inhibition) 
and delayed when pi integrin activation was inhibited (investigated by chemical 
inhibition).
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6. Discussion
Eosinophil granule proteins are very important and unique for eosinophils. They 
are cationic in nature and not a lot is known about their function in epithelial cells, 
even though much is known of their function in nerve cells. With regards HER2, 
many studies have investigated their role in signalling but not a lot of research 
has been carried out on the receptor itself. Before this study, no previous soluble 
ligand was known for the HER2 receptor. We found N-linked glycosylation, HER2 
activation and also pi integrin activation to be very important in EPO-induced cell 
signalling, via the HER2 receptor. We have elucidated a reproducible system of 
signalling that occurs in response to EPO exposure.
This study was designed to investigate the mechanism of action of eosinophils. It 
is important to understand how eosinophils function since they exist in many 
disease states as well as many other physiological conditions in which there is 
increased cell turnover. With asthma being of particular interest to our laboratory, 
we focused our investigation on eosinophils and in particular one of the 
eosinophil granule proteins, eosinophil peroxidase (EPO) and how this protein 
affects epithelial cells.
One of the limitations of this study is that all of the experiments were performed 
in a transformed normal human bronchial epithelial cell line. This was necessary 
in order to ensure the hypothesis held before being able to design the 
appropriate experiments in human primary epithelial cells. One of the reasons 
working with a cell line is considered a limitation is the fact that the cells are 
cultured un-polarised. Similar experiments using the cell lines cultured on 
transwells at an air-liquid interface, or using primary epithelial cells grown either 
as monolayers or well-differentiated polarised epithelium would provide a closer 
representation of what occurs in vivo. Due to time-constraints our hypothesis has 
not been tested in human primary epithelial cells, however, this is a project that 
will hopefully be continued in the laboratory in the future.
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Another limitation in the study is the range of proteins and treatment 
concentrations we were able to investigate in this system. A range of EPO doses 
were tested, but not a huge spectrum, this was because a dose of 4pg/ml, which 
is close to physiological concentration, was sufficient to induce a response within 
the cell and more importantly, did not have any apoptotic effect on our cell line. In 
terms of investigating a wider range of proteins, with more time it would have 
been interesting to test a lot of these results with other eosinophil granule 
proteins, in order to fully determine how specific the EPO, HER2 relationship is. 
Even when considering the experiments using EPO as the treatment, there are 
other cell surface molecules that are of interest of us to investigate, such as the 
other HER family receptors and other members of the integrin family. Knowledge 
of the effect of EPO on these molecules and indeed their interaction with HER2 
should allow us to further understand the nature of the interaction between EPO 
and HER2 and to also understand in more detail the exact signalling pathways 
activated in response to EPO.
This project was rationally designed based on a proteomic screen with EPO 
treated IMR32 nerve cells. Interesting results from that proteomic screen 
included an EPO-induced 2.7-fold increase in the levels of pFAK at its 
autophosphorylation site Y397, and also an EPO-induced 2.61-fold increase in 
the levels of pHER2 at its autophosphorylation site Y1248. The early stages of 
the project involved testing and confirming that these effects were also occurring 
in the 16HBE14o cell line, which was used throughout this project. Hence, while 
the basis of the study was information from nerve cells, the observation was also 
true in epithelial cells, suggesting that this is an important and generalisable 
finding.
The main significance of this work is the discovery of the first known soluble 
ligand for the HER2 receptor, and consequently the discovery of a novel receptor 
for eosinophil peroxidase. The activation of the HER2 receptor by EPO is
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interesting because both EPO and HER2 have been found to be upregulated in 
disease states such as cancer. A characteristic feature of an asthmatic airway is 
increased eosinophil presence and our results show that when epithelial cells are 
exposed to EPO, there is an increase in HER2 receptor expression. As 
discussed in the Introduction, HER2 and other growth factor receptors activate 
many signalling pathways involved in growth, proliferation and survival. Hence, 
this result alone indicates a role of EPO in remodelling in the asthmatic airway.
EPO induced the activation of pi integrin, and our results suggest that pi integrin 
interacts with HER2 to activate downstream signalling molecules such as ERK. 
This is in line with previous studies linking integrins and growth factor receptors 
in the activation of various cellular signalling pathways. Here we have shown that 
EPO mediates the interaction of these two cell surface proteins by first activating 
the HER2 receptor, then activating the signalling protein FAK. FAK can be 
activated by both growth factor receptors and integrins and FAK is a scaffold 
protein which acts as a link between HER2 and pi integrin. Our results show that 
when we silence FAK, there is no longer an EPO-induced upregulation in the 
levels of active pi integrin, so the presence of FAK is vital in mediating the EPO 
induced activation of pi integrin. The activation of pi integrin is necessary for the 
EPO-induced activation of FAK. This protein cluster of HER2, pi integrin and 
FAK is likely to be of key significance in further downstream signalling events 
involved in remodelling within epithelial cells.
The result showing EPO-induced activation of ERK highlights the complexity of 
the system we are investigating. EPO induces a time-dependent increase in the 
levels of pERK, and this is dependent on N-linked glycosylation. Preliminary 
results suggest that silencing HER2 results in no activation of ERK by EPO, 
whereas when we inhibit the tyrosine kinase activity of ERK, an EPO-induced 
increase in pERK still occurs. A possible explanation for the contradictory results 
between the two methods could be that when the tyrosine kinase activity of 
HER2 is inhibited, signalling may still occur through a partner protein, for
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example MUC4, or through another EGFR family member (as HER2 is the 
preferred binding partner of the other family members).
EPO-induced upregulation of MUC4 gene expression indicates that eosinophils 
may also contribute to increased mucociliary clearance during an inflammatory 
attack.
In other hypereosinophilic diseases, although there is an excess in eosinophil 
presence, there is not typically excessive mucus production. The presence of 
HER2 in these disease states has not been investigated in detail and as 
mentioned previously MUC4 is a tethered ligand for HER2. If MUC4 is not 
expressed in some cell types of hypereosinophilic disorders ie. the heart, skin 
and blood then EPO interacting with HER2 would not result in the mucus 
overproduction as seen in bronchial epithelial cells. We cannot however rule out 
the possibility that EPO may still signal via HER2 in these other 
hypereosinophilic conditions as HER2 dimerises with other EGFR family 
members to exert its intracellular effects.
Our results show in summary (Diagram 11), that EPO forms a complex with the 
HER2 receptor, resulting in activation of the HER2 receptor. EPO induces 
activation of FAK via HER2 and FAK acts as a scaffold protein bringing together 
P1 integrin and the HER2 receptor. There is subsequent EPO-induced activation 
of pi integrin. The interaction of either HER2 with pi integrin, HER2 with MUC4, 
or HER2 with another EGFR family member (or indeed another cell surface 
protein not investigated here) results in the EPO-induced activation of ERK MAP 
Kinase, which we know to be mediated via N-linked glycosylation.
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Diagram 11. Final Summary
uiieidiAiui i
/ c o n s e q u e n c e  o f in terac tio n  ie . F A K  ac tiva tio n
\ le ad in g  to  E R K  ac tiva tio n
V p o ten tia l in te rac tio n s  le ad in g  to  E R K  ac tiva tio n
+ ca tio n ic  E P O
- ©
t
p h o s p h o ry la te d
in s id e -o u t  
in tegrin  s ign a llin g
These results suggest that eosinophil localisation to epithelial cells, as seen in 
asthma and rhinitis induces growth factor receptor expression and subsequent 
downstream pathways associated with cell proliferation, all of which are 
necessary for the airway to repair and remodel after an inflammatory episode. 
This brings rationale to investigate inhibitors of these pathways, which could 
prove useful when eosinophil presence is prolonged or when eosinophil 
concentration is too high in the airway. These circumstances result in EPO 
having a pathological effect within the airway. Understanding the exact 
mechanism of interaction between EPO and the epithelial cell as well as further 
understanding its downstream effects, could potentially allow us to provide 
intervention treatment before EPO concentration tips the balance from being 
helpful to becoming pathological.
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